Articles tagged with Cancer Patients
A new study from Huntsman Cancer Institute suggests that family members of children with cancer may be at higher risk of developing childhood cancer, depending on their family medical history. The research recommends collecting three generations of family medical history for all newly diagnosed pediatric cancer patients.
Scientists have discovered a new biomarker that predicts how well cancer patients respond to cancer drugs. The biomarker, linked to PRL-3 protein levels, identifies patients who are most likely to benefit from existing anti-cancer treatments, reducing healthcare costs and potentially saving lives.
A new study reveals that certain patient groups feel unmet needs for greater involvement in cancer treatment decisions. Younger patients and those with specific rare types of cancer want more input in the decision-making process. The research emphasizes the importance of shared-decision making policies to address these disparities.
The Louisiana Tumor Registry has been awarded a contract to continue its work as a SEER Program-designated cancer registry, collecting cancer incidence and survival data from 28% of the US population. The funding will support cancer research, including prevention, early detection, treatment, and survivorship studies.
Researchers at Fred Hutchinson Cancer Center are pioneering a new approach to harness the power of the adaptive immune system to control cancer. They are using high-throughput technology and large-scale data mining to identify potential immune targets and verify their immunogenicity.
A portable diagnostic device developed by Chinese researchers can travel to patients anywhere in the world, providing an opportunity for early cancer detection. The device uses microfluidics technology and is designed to be low-cost, easy-to-use, and power-independent.
Researchers found that women with atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) can avoid surgery if radiologist and pathologist findings are concordant. Yearly mammograms, MRI, or ultrasound as second-line screening tools may suffice.
A scientific panel recommends personalized strategies to reduce cancer overtreatment by classifying indolent tumors and improving screening strategies. The goal is to detect consequential cancer while avoiding inconsequential disease.
A new study published in JAMA Internal Medicine found that decision aids increased men's knowledge and reduced conflict about PSA screening, but did not impact their decisions. The tools were equally effective in improving knowledge and reducing decisional conflict.
New study reveals stable survival rates for HIV-associated lymphoma patients during the antiretroviral therapy era. Despite increased incidence and changing demographics, recent diagnosis years are not associated with decreased mortality. The study highlights an ongoing need to improve treatments for this challenging population.
Researchers discovered a function of PTEN that helps explain why certain therapies fail in many cancer patients. The finding increases understanding of molecular mechanisms and provides clues for individualizing therapy for patients with PTEN-deficient tumors.
Scientists at Ohio State University have identified two regions on the HER1/EGFR receptor as potential targets for peptide-based cancer vaccines and therapeutic agents. These peptides show promise in inhibiting tumor growth in breast and lung cancer models.
A Swedish data-sharing campaign led to a significant decrease in unnecessary medical tests for low-risk prostate cancer patients. The study suggests that curtailing unneeded medical tests is achievable and offers insights into the importance of implementing guidelines and providing feedback to practitioners.
A new study found that only 40% of young female cancer patients were happy with the way their doctors discussed fertility preservation options. The study suggests a need to rethink how fertility issues are discussed with young people diagnosed with cancer, both in terms of timing and content.
Researchers found that approximately 13% of smokers used e-cigarettes as a means of quitting, with younger smokers more likely to use them. E-cigarette users were also found to be more motivated to quit smoking compared to those who tried other cessation aids.
Researchers have found that elevated levels of a receptor protein called Ret are associated with lower survival rates in breast cancer patients. Inhibiting this protein may be a promising approach to treating the disease.
Prehabilitation interventions, including physical and psychological support, can reduce treatment-related complications, improve physical and mental health outcomes, and increase treatment options. Benefits include lower complication rates, reduced hospital readmissions, and improved healthcare costs.
Researchers have developed a promising new cancer treatment, PAC-1, which targets a cellular enzyme to spur cancer cells to self-destruct. The compound has shown safe and anti-cancer effects in cell culture, mouse models, and pet dogs with spontaneously occurring cancers.
Researchers developed an 'intelligent knife' that can identify cancerous tissues during surgery, providing instant results. The technology, called iKnife, was tested on 91 patients and showed 100% accurate diagnosis, potentially reducing tumour recurrence rates and improving patient outcomes.
A pilot study by TGen and Scottsdale Healthcare shows that personalized cancer treatment based on molecular profiling improves clinical benefits, with 52% of advanced breast cancer patients experiencing disease control. The study demonstrates feasibility of personalized cancer treatment and sets the stage for a larger study.
Cardiovascular screening is crucial for cancer patients who received chest radiation, especially those at high risk of developing radiation-induced heart disease (RIHD). The European Society of Cardiology recommends regular screenings to detect cardiac abnormalities and reduce the risk of death from coronary artery disease.
Researchers found that people with Hyper IgE Syndrome have more redundancy in their immune systems than expected, allowing them to respond effectively to most viruses and cancers. This discovery highlights the differences between mouse model work and real human infectious diseases, providing valuable insights for clinical treatment.
Researchers have developed a new method for identifying cell of origin of proteins in multicellular environments, enabling comprehensive mapping of cell-cell communication. This technique, CTAP, exploits amino acid biosynthesis and stable isotope labeling to link proteins directly to specific cell types.
A new analysis found that African Americans with chronic lymphocytic leukemia present with advanced disease and have shorter survival times than Caucasians. The study suggests that biological factors may account for racial disparities in cancer survival.
Researchers from the University of Liverpool and University of the West of England have developed a device that can detect bladder cancer through urine scent analysis. The ODOREADER device analyzes chemicals in gas emitted from urine to produce a 'profile' that can be used to diagnose cancer cells in the bladder.
Researchers at Helmholtz Association discovered that exercise can fully rescue the phenotype of CHD7-deficient neural stem cells, allowing them to differentiate into mature neurons. This breakthrough provides new insights into the molecular mechanisms underlying CHARGE syndrome and may lead to potential treatments.
A study found that access to healthcare is a key driver in the increasing incidence of thyroid cancer. Insured individuals are more likely to be diagnosed with thyroid cancer than those without insurance, highlighting the need for targeted measures to prevent overdiagnosis.
A high HOXB13/IL17BR ratio in tumor tissue indicates increased risk of recurrence after tamoxifen therapy, but drops significantly if a patient receives letrozole. This biomarker can help identify patients who may benefit from extended treatment with letrozole.
Researchers created educational materials to empower Spanish patients to make health care decisions, addressing language barriers and cultural ideas that hinder participation. The study aims to improve knowledge and participation for Hispanic patients in clinical trials.
A study published in the Journal of the American College of Surgeons found that melanoma recurrence 10 or more years after initial treatment occurs in over 6% of patients. Patients who experience late recurrences tend to live longer and have better survival rates compared to those whose cancer recurs within the first three years.
Researchers at USC Norris Comprehensive Cancer Center have discovered a promising new way to treat primary effusion lymphoma (PEL), a rare and aggressive blood cancer often found in people with HIV. BRD4 inhibitors show effectiveness against PEL, which has a poor prognosis, offering hope for new therapies.
A recent study published in the Journal of the American College of Cardiology found that heart failure patients are more likely to develop cancer, with a significant increase in mortality rates. The study suggests that side effects of cardiovascular treatments and inflammation may be contributing factors.
Researchers found that brain tumor cells with intact IDH gene produce a key enzyme BCAT1, which boosts cell proliferation. Blocking BCAT1 reduced tumor aggressiveness and released neurotransmitter glutamate. The study suggests using BCAT1 as a therapeutic target for glioblastoma treatment.
Scientists have discovered a connection between the aggressiveness of kidney cancer and changes in how tumor cells use energy from metabolic processes. The study found that certain proteins are associated with worse patient outcomes, while others may be used as therapeutic targets.
A phase Ib/II trial showed an overall response rate of 71% for CLL patients and a 68% response rate for MCL patients, with estimated progression-free survival rates of 75% and 58% respectively. Ibrutinib has been shown to target Bruton's tyrosine kinase, a protein critical in B-cell receptor pathway for tumor cell survival.
A recent study published in Oncogene identified a biochemical pathway in cancer stem cells that is essential for promoting head and neck cancer. The study shows that the Nanog protein, normally active in embryonic stem cells, promotes the growth of cancer stem cells in head and neck cancer.
The study found that the median time to activation of phase 1-2 trials decreased from 541 to 442 days, and for phase 3 trials from 727 to 395 days. The reforms led to faster initiation of NCI-sponsored trials, ultimately benefiting patients in need of new treatments for cancer.
A new minimally invasive procedure called CELS allows doctors to remove large and hard-to-reach polyps while keeping the colon intact. The procedure has been shown to have lower complication rates and shorter hospital stays compared to standard surgery.
A study at Ohio State University Comprehensive Cancer Center identified a mesenchymal subtype of glioblastoma as the most aggressive and lethal form of brain cancer. The mesenchymal subtype is characterized by high levels of the enzyme ALDH1A3, which drives tumor growth and resistance to radiation.
Researchers found that telephone-based counseling combined with physician advice increased physical activity among breast cancer survivors by 30 minutes per week. The study also showed significant improvements in patients' motivational readiness and overall well-being.
Researchers at Uni Basel have discovered Sox4 as a key player in cancer metastasis, triggering the epithelial-mesenchymal transition (EMT) process. The study found that Sox4 promotes the expression of genes involved in EMT and metastasis, leading to changes in gene expression and cell behavior.
A new study reveals that hormonal treatment for endometrial cancer works by binding to stromal tissue cells, rather than directly targeting cancerous cells. Researchers hope to develop a simple test to determine patient suitability for progesterone therapy.
A new method of dose calculation estimates radiation absorbed dose in radioimmunotherapy, predicting progression-free survival and enabling personalized treatment. Patients receiving higher doses (>200 centigray) had significantly longer progression-free survival.
Researchers at Moffitt Cancer Center found that chronic myeloid leukemia patients taking tyrosine kinase inhibitors experience distressing side effects such as depression, fatigue, nausea, and changes in appearance. These issues can significantly impact patients' quality of life for the rest of their treatment period.
A new study found that virtual colonoscopy screenings can be safely delayed for women by 5-10 years compared to men, with minimal impact on cancer detection rates. The findings suggest that women under 55 may only need to undergo screening every 10 years, while those over 60 can wait up to 5 years longer.
Researchers identified novel FGFR gene fusions across various cancer types, suggesting potential therapeutic targets for patients. The study's findings have the potential to identify actionable mutations that can be treated with precision therapies.
Researchers have identified a new biomarker for colorectal cancer detection using serum DNA analysis, detecting 87% of all stages of CRC cases. The SDC2 methylation test has high sensitivity and specificity, making it a promising non-invasive alternative to colonoscopy.
Researchers found that nearly three-quarters of high-grade bladder cancer patients experience disease return within 10 years. Intensive surveillance and treatment can reduce recurrence rates, with a single instillation of chemotherapy showing promise in minimizing recurrences.
A recent study reveals that cancer survivors are significantly more likely to experience anxiety, with partners experiencing even more anxiety than survivors. The findings highlight the need for improved screening and follow-up support for both survivors and their families.
A UK study reveals that despite national recommendation, only 47.4% of terminally ill patients are placed on the Liverpool Care Pathway for end-of-life care. Lack of knowledge and staff support may be contributing factors to its underutilization.
Mount Sinai researchers identified genetic markers for survival in melanoma patients and found high readmission rates after cancer surgery in non-teaching hospitals and among black patients. They also discovered low prevalence of spousal HPV infection, reassuring long-term partners that their risk is very low.
Researchers found that the experimental drug selumetinib significantly improved progression-free survival, with nearly 16 weeks of PFS, and showed significant tumor shrinkage in patients with advanced uveal melanoma. This breakthrough offers a new treatment option for a historically untreatable disease.
Researchers found that cytomegalovirus (CMV) can speed the progression of glioblastoma, a deadly form of brain cancer, when particular genes are shut off. CMV was found to stimulate tumor-cell proliferation by activating a biochemical cell pathway called STAT3.
A phase II clinical trial identified patients with HPV-positive oropharyngeal cancer who may not require full radiation doses. Most patients tolerated the treatment with low incidence of high-grade side effects, but larger tumors and heavy smoking history predicted worse outcomes.
A 16-year-old student, Matthew Lara, will present his research on the predictors of survival for younger patients with non-small-cell lung cancer at the American Society of Clinical Oncology (ASCO) meeting. His study found that younger patients tend to have better survival rates than older patients.
Researchers have developed a device that captures and isolates potentially high-risk cancer cells, enabling doctors to access and identify cancerous cells in the bloodstream. This technology may revolutionize conventional biopsy practices and significantly advance personalized medicine.
A large-scale study has shown that immunological stool tests are more sensitive than enzyme-based tests in detecting colon cancer and precancerous lesions. The tests detected about twice as many cancer cases and three times as many advanced precancerous lesions, with a higher specificity rate.
A new study from Beth Israel Deaconess Medical Center found that doctors treating patients with kidney failure are reluctant to discuss a difficult prognosis, leading to distorted expectations about probable outcomes. The study suggests improved communication could help with end of life decision making.
A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can effectively spot tiny lung nodules indicating the earliest stages of disease. LDCT uses less than a quarter of the radiation of a conventional CT scan, resulting in a higher detection rate compared to chest x-rays.
A 14-year study found older men with multiple health issues were at higher risk of dying from other causes, making watchful waiting a viable option for low- to intermediate-risk prostate cancer patients.